A Robot Can Now Draw Blood—What the FDA Actually Authorized

The next robot many people encounter may not walk, talk or carry a
box. It may ask them to place an arm inside a machine—and then draw
their blood.

On 19 August 2026, the US Food and Drug Administration authorized
Aletta, which it describes as the first standalone robotic device
able to draw blood from an adult’s arm without hands-on operator
intervention. That is a meaningful step for medical robotics, but
“autonomous” does not mean unsupervised. Aletta is authorized for adult
patients in outpatient settings, and every session must take place under
the oversight of a professional trained in phlebotomy.

How Aletta finds a vein and draws blood

A conventional blood draw depends heavily on a phlebotomist’s vision,
touch and experience. Aletta converts much of that process into a
sequence of imaging, sensing and robotic actions.

After collection tubes are loaded and the patient positions an arm,
the device uses near-infrared light to help map veins near the skin.
Ultrasound provides a deeper view, while Doppler ultrasound checks blood
flow so the system can distinguish a vein from an artery. If its
software cannot identify an appropriate vein, the machine does not
insert a needle.

When a suitable target is found, Aletta can apply a tourniquet, clean
the skin, insert the needle, fill and invert multiple tubes, remove and
dispose of the needle, and apply a bandage. The FDA’s
description of the workflow also includes safety responses:
excessive patient movement causes the needle to detach and the draw to
stop, while other sensors can pause the procedure and alert the
supervisor.

The human role has not disappeared. A trained phlebotomist initiates
the session, remains available if the system encounters a problem,
checks the order of the tubes and confirms that they are adequately
filled. The authorization permits one trained supervisor to oversee up
to three devices.

Aletta’s ADOPT trial: blood-draw results and limitations

The strongest published evidence comes from the multicentre
ADOPT trial in Clinical Chemistry, registered as NCT05878483.
Researchers studied an investigational version of the robotic device in
outpatient departments in the Netherlands.

In the trial’s larger routine-use cohort, 1,743 people completed the
device’s vein screening. Aletta did not identify a suitable vein in 110
people, or about 6%, so those patients were referred for a manual draw.
It attempted venipuncture in the remaining 1,633 and succeeded on the
first stick in 1,543 cases—a first-stick success rate of 94.5% among
attempted procedures.

That denominator matters. If all 1,743 screened patients are counted,
88.5% received a successful first-stick robotic collection. This
FutureTechDose calculation does not contradict the published 94.5%
result; it answers a different question. The higher figure describes
performance after the robot accepts a case, while the lower figure shows
how often screening ended in a successful robotic draw.

Performance remained high in several groups that can present
challenges during blood collection: 92.7% among participants reporting
difficult venous access, 93.4% among those aged 65 or older, and 97.4%
among participants with obesity. Ten of the 1,633 attempted procedures,
or 0.6%, were associated with adverse events, all classified as mild;
the paper reported no moderate or serious adverse events.

Patient responses were broadly positive. Among survey respondents,
90% said the robotic draw caused less, far less or similar pain compared
with a manual draw. Eighty-two per cent either preferred the robot for a
future draw or had no preference.

Encouraging
evidence, with important limits

The results do not establish that Aletta is better than an expert
phlebotomist in every clinic. The large routine-use cohort had no
simultaneous manual-control group; the authors compared its results with
performance ranges reported in earlier literature. The system also
declined cases in which it could not find a suitable vein, whereas a
human team still had to manage those patients.

A separate 153-person cohort compared samples collected robotically
and manually from the same participants. Researchers found no
statistically significant differences across five selected measurements:
activated partial thromboplastin time, prothrombin time, lactate
dehydrogenase, aspartate aminotransferase and platelet count. That is
useful reassurance, but it is not proof of equivalence for every
laboratory test.

The paper reported a low overall haemolysis rate—the breakdown of red
blood cells that can spoil a sample—but results varied by study site,
and the manual comparison was not randomized. Patient-experience
questionnaires were not completed by everyone, creating the possibility
that respondents differed from non-respondents.

There is also a financial-disclosure caveat. Vitestro funded the
study, several authors were company employees or equity holders, and the
sponsor participated in study design, patient selection, data
interpretation and manuscript preparation. Peer review and transparent
disclosures strengthen the evidence, but independent real-world studies
will still be valuable.

Authorization
is not the same as instant rollout

The FDA used its De
Novo pathway, which is intended for novel low- to moderate-risk
devices without an existing legally marketed comparator. The decision
gives Vitestro US marketing authorization and establishes general and
special controls for this new device type. It is more precise to call
Aletta “FDA-authorized” than simply “FDA-approved.”

Authorization also does not mean the machine will immediately appear
in every American blood-collection centre. In its 20
August company announcement, Vitestro said it would scale
manufacturing and prepare a phased US rollout, with European deployment
occurring first. The company also plans a US multicentre study before
commercial availability there. Hospitals will still have to assess
training, workflow, maintenance, cost, throughput and how often patients
need manual assistance.

Why this matters

Aletta is notable because it automates a physical clinical procedure,
not merely an administrative task or image-analysis step. It combines
sensing, decision-making and precise movement while touching a
patient—yet it is deliberately placed inside a supervised healthcare
workflow.

The most realistic near-term impact is therefore not a clinic without
phlebotomists. It is a clinic where trained staff supervise several
routine draws, intervene when a case is unsuitable and spend more time
on patients who need human judgment. Whether that model improves waiting
times and costs will depend on real-world deployment data, not the
authorization alone.

Reporting note

This article is based on the FDA authorization announced on 19 August
2026, the peer-reviewed ADOPT trial and current manufacturer
documentation. The pivotal routine-use cohort was single-arm, the
sponsor funded and participated in the research, and the published study
evaluated an investigational version of the device. Commercial
performance may differ as Aletta enters broader clinical use.

The challenge of precise movement extends across robotics. See why robot hands are so difficult to build.

Sources and further reading

1. US
   Food and Drug Administration: FDA Authorizes First-Of-Its-Kind Robotic
   Blood Draw Device
2. Giesen
   et al., Clinical Chemistry: Performance, Safety, and Patient
   Experience of an Autonomous Robotic Phlebotomy Device
3. ClinicalTrials.gov:
   Autonomous Blood Drawing Optimization and Performance Testing
   (NCT05878483)
4. FDA:
   De Novo Classification Request
5. Vitestro: Aletta product and
   clinical-evidence overview
6. Vitestro:
   FDA De Novo authorization and rollout announcement

FutureTechDose covers biotechnology, AI, robotics, data-centre and
energy-sector research and industry progress for a general audience.
This article is informational and does not provide medical or investment
advice.